Cancer Immunotherapies Market to Exhibit 15% CAGR from 2016 to 2020

0
156
Cancer Immunotherapies Market
Cancer Immunotherapies Market

A detailed market research report covering the global market for cancer immunotherapies has been recently added to the vast research report portfolio of MarketResearchReports.biz. The report, titled “Global Cancer Immunotherapies Market 2016-2020,” states that the market will exhibit a promising CAGR of 15% from 2016 to 2020.

A number of factors working in collaboration will act in favor of immunotherapies and their use in the treatment of a variety of cancers. The report states that an encouraging rise in patient assistance programs across the globe will prove to be the most beneficial driver for the market during the foreseen period. Owing to an increasingly heated level of competition, leading vendors are providing co-pay assistance to patients who are buying prescribed medicines for a number of treatments. Roche’s Genentech Access Solutions is one such example of a co-pay program that covers the cost of treatment of patients using Herceptin or provide options of co-pay assistance or reimbursement support to patients if they satisfy some criteria.

The market is also expected to be fueled owing to the presence of a strong pipeline of novel treatment methods and drug classes targeting the rising set of cancers and the set of population they affect globally. A number of companies have started investing in research and development activities in the field and a number of new varieties of drug candidates with the promise of a high safety profile and efficacy are also being developed. This encouraging scenario will add significant traction to the global market for immunotherapies for cancer.

On the basis of type, the report segments the global cancer immunotherapies market into immune checkpoint inhibitors, cancer monoclonal antibodies, cancer vaccines, and non-specific immunotherapies. The report states that the segment of monoclonal antibodies registered a clear dominance, accounting for over 70% of the overall market in 2015. Over the past few years, there has been a massive rise in usage of monoclonal antibodies in a variety of therapies such as antibody-directed enzyme prodrug and radioimmunotherapy. Monoclonal antibodies are also finding increased usage in the treatment of a variety of cancers as they can attack a particular part of cancer cells.

For Sample Copy, click here: https://www.marketresearchreports.biz/sample/sample/715922

In terms of geography, the cancer immunotherapies market has been examined in the report for regions such as Americas (North and South America), Asia Pacific (APAC), and Europe. Of these, the cancer immunotherapies market in Americas held a dominant share of 47% of the global market in 2015. The region leads in terms of demand and revenue generations opportunities when it comes to cancer immunotherapies owing to a vast and rising patient pool of cancer in major countries. The region is expected to remain one of the leading hubs for the development of the cancer immunotherapies market over the report’s forecast period.

A detailed overview of the vendor landscape of the market is also included in the report, illustrating the various opportunities and threats ahead of these vendors in the overall market. The report states that the global market for cancer immunotherapies features a largely competitive vendor landscape owing to a large number of small and large vendors operating on a global scale.

Some of the leading companies in the market are Bristol Mayer’s Squibb, Amgen, Takeda, F. Hoffmann-La Roche, Merck, Pfizer, AbbVie, Chugai Pharmaceutical, Boehringer-Ingelheim, Biogen, ADC Therapeutics, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Eli Lilly, Morphotek, Oncomed Pharmaceuticals, Biotech Pharmaceuticals, CTI BioPharma, Sanofi, Daiichi Sankyo, Janssen Biotech, Astellas, Kyowa Hakko Kirin, Genmab, Celldex Therapeutics, Novartis, Seattle Genetics, Fortress Biotech, Agensys, Xbiotech, AstraZeneca, Immunomedics, Neovii Biotech, Bayers, TG Therapeutics, and MedImmune.

Leave a Reply